Latest news with #BacillusCalmette-Guerin
Time of India
29-04-2025
- Time of India
GSVM student found dead in hostel
Kanpur: A paramedical student at Ganesh Shankar Vidyarthi Memorial Medical College in Kanpur ended his life in his room at the college hostel in Swaroop Nagar police station area on Tuesday afternoon. After the student did not answer the calls, his father reached the hostel. On breaking open the door of his room, his body was found inside. The police have initiated an investigation after sending the body for an autopsy. Arvind, 19, son of Moti Lal, a resident of Bamharoula village in the Marka police station area of Banda district, was a first-year BCG (Bacillus Calmette-Guerin) technician student at the medical college. He took admission in Dec, 2024. According to his father, he went to college from home on Friday. He had the last conversation with his family at 3pm on Saturday and after that his phone was unreachable. When the family members couldn't contact him on Sunday and Monday evening, they reached his hostel late on Monday night. His room was found locked from inside and there was no response to repeated knockings. His father informed the police. The police, along with forensic team, broke the door and found youth's body. Inspector Suryabali Pandey of Swarupnagar stated that student committed suicide. "The body has been sent for post-mortem, and further action will be taken based on the report," he added.
Business Insider
28-04-2025
- Health
- Business Insider
Pfizer announces Phase 3 CREST trial met primary endpoint of EFS
Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, NMIBC. The trial met its primary endpoint of event-free survival, EFS, by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG as compared to BCG alone: Hazard Ratio of 0.68; 95% Confidence Interval, 0.49-0.94; 2-sided p=0.019; median EFS not yet reached. These findings show a 32% reduction in risk of disease-related events, including high-grade disease recurrence or progression, with the sasanlimab combination regimen as compared with SOC treatment alone. Pre-specified subgroup analyses for patients harboring higher risk disease showed consistent benefit with EFS HR of 0.63 for T1 disease, and EFS HR 0.53 for those with CIS disease. Stay Ahead of the Market:
